ScholarX

Browsing by Girard, NicolasAuthor

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하

Showing results 1 to 16 of 16

SCOPUS
A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion–mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS studyopen access

Girard, Nicolas; Park, Keunchil; Lee, Se-Hoon; Viteri, Santiago; Schioppa, Claudio A.; Diels, Joris; Oguz, Mustafa; Rodrigues, Bernardo H.; Rahhali, Nora; Sermon, Jan, et al.

ArticleIssue Date2024CitationCancer Treatment and Research Communications, v.40PublisherElsevier Ltd
SCIESCOPUS
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Studyopen access

Park, Keunchil; Haura, Eric B.; Leighl, Natasha B.; Mitchell, Paul; Shu, Catherine A.; Girard, Nicolas; Viteri, Santiago; Han, Ji-Youn; Kim, Sang-We; Lee, Chee Khoon, et al.

ArticleIssue Date2021CitationJOURNAL OF CLINICAL ONCOLOGY, v.39, no.30, pp 3391 - 3402PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

Zhou, Caicun; Tang, Ke-Jing; Cho, Byoung Chul; Liu, Baogang; Paz-Ares, Luis; Cheng, Susanna; Kitazono, Satoru; Thiagarajan, Muthukkumaran; Goldman, Jonathan W.; Sabari, Joshua K., et al.

ArticleIssue Date2023CitationNEW ENGLAND JOURNAL OF MEDICINE, v.389, no.22, pp 2039 - 2051PublisherMASSACHUSETTS MEDICAL SOC
SCIESCOPUS
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLC

Cho, Byoung C.; Lu, Shun; Felip, Enriqueta; Spira, Alexander I.; Girard, Nicolas; Lee, Jong-Seok; Lee, Se-Hoon; Ostapenko, Yurii; Danchaivijitr, Pongwut; Liu, Baogang, et al.

ArticleIssue Date2024CitationNEW ENGLAND JOURNAL OF MEDICINEPublisherMASSACHUSETTS MEDICAL SOC
SCIESCOPUS
Amivantamab plus lazertinib vs osimertinib in first-line EGFR<i>-</i>mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study

Felip, Enriqueta; Cho, Byoung Chul; Gutierrez, Vanesa; Alip, Adlinda; Besse, Benjamin; Lu, Shun; Spira, Alexander I.; Girard, Nicolas; Califano, Raffaele; Gadgeel, Shirish M., et al.

ArticleIssue Date2024CitationJOURNAL OF CLINICAL ONCOLOGY, v.42, no.16PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd)

Sands, Jacob; Lisberg, Aaron; Bardia, Aditya; Shimizu, Toshio; Ahn, Myung-Ju; Paz-Ares, Luis G.; Meric-Bernstam, Funda; Kitazono, Satoru; Krop, Ian E.; Girard, Nicolas, et al.

ArticleIssue Date2024CitationJOURNAL OF CLINICAL ONCOLOGY, v.42, no.16PublisherLIPPINCOTT WILLIAMS & WILKINS
SCOPUS
Case presentations and recommendations from the 2018 ITMIG Annual Meetingopen access

Sigurdson, Samantha; Moideen, Nikitha; Marom, Edith M.; Szolkowska, Malgorzata; Roden, Anja C.; Rajan, Arun; Girard, Nicolas; Marino, Mirella; Noh, Jae Myoung; Kirk, Alan, et al.

ArticleIssue Date2020CitationMediastinum, v.4PublisherAME Publishing Company
SCIESCOPUS
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

Atmaca, Akin; Ahn, Myung-Ju; Lisberg, Aaron; Paz-Ares, Luis; Cornelissen, Robin; Girard, Nicolas; Pons-Tostivint, Elvire; Baz, David Vicente; Sugawara, Shunichi; Cobo, Manuel Angel, et al.

ArticleIssue Date2024CitationONCOLOGY RESEARCH AND TREATMENT, v.47, pp 245 - 245PublisherKARGER
SCIESCOPUS
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Ahn, Myung-Ju; Tanaka, Kentaro; Paz-Ares, Luis; Cornelissen, Robin; Girard, Nicolas; Pons-Tostivint, Elvire; Vicente Baz, David; Sugawara, Shunichi; Cobo, Manuel; Pérol, Maurice, et al.

ArticleIssue Date2025CitationJournal of Clinical Oncology, v.43, no.3PublisherLippincott Williams and Wilkins
SCIESCOPUS
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%

Johnson, Melissa Lynne; Arriola, Edurne; Kato, Terufumi; Girard, Nicolas; Gadgeel, Shirish M.; Wang, Jie; Li, Xia; Lowery, Caitlin; Krug, Lee M.; Ahn, Myung-Ju

ArticleIssue Date2024CitationJOURNAL OF CLINICAL ONCOLOGY, v.42, no.16PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary diseaseopen access

Zhou, Chengzhi; Qin, Yinyin; Zhao, Wei; Liang, Zhenyu; Li, Min; Liu, Dan; Bai, Li; Chen, Yahong; Chen, Yan; Cheng, Yuan, et al.

ArticleIssue Date2023CitationTRANSLATIONAL LUNG CANCER RESEARCH, v.12, no.8, pp 1661 - 1701PublisherAME PUBLISHING COMPANY
SCIESCOPUS
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Spicer, Jonathan D; Garassino, Marina C; Wakelee, Heather; Liberman, Moishe; Kato, Terufumi; Tsuboi, Masahiro; Lee, Se-Hoon; Chen, Ke-Neng; Dooms, Christophe; Majem, Margarita, et al.

ArticleIssue Date2024CitationThe Lancet, v.404, no.10459, pp 1240 - 1252PublisherElsevier B.V.
SCIESCOPUS
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722open access

Mok, Tony; Nakagawa, Kazuhiko; Park, Keunchil; Ohe, Yuichiro; Girard, Nicolas; Kim, Hye Ryun; Wu, Yi-Long; Gainor, Justin; Lee, Se-Hoon; Chiu, Chao-Hua, et al.

ArticleIssue Date2024CitationJournal of Clinical Oncology, v.42, no.11, pp 1252 - 1264PublisherLippincott Williams and Wilkins
SCIESCOPUS
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC

Hochmair, Maximilian J.; Vermaelen, Karim; Mountzios, Giannis; Carcereny, Enric; Dooms, Christophe; Lee, Se-Hoon; Morocz, Eva; Kato, Terufumi; Ciuleanu, Tudor-Eliade; Dy, Grace K., et al.

ArticleIssue Date2024CitationEuropean Journal of Cancer, v.208PublisherElsevier Ltd
SCIESCOPUS
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

Camidge, D. Ross; Bar, Jair; Horinouchi, Hidehito; Goldman, Jonathan; Moiseenko, Fedor; Filippova, Elena; Cicin, Irfan; Ciuleanu, Tudor; Daaboul, Nathalie; Liu, Chunling, et al.

ArticleIssue Date2024CitationJournal of Clinical Oncology, v.42, no.25PublisherLippincott Williams and Wilkins
SCIESCOPUS
TROPION-Lung07: Phase III study of Dato-DXd plus pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung canceropen access

Okamoto, Isamu; Kuyama, Shoichi; Girard, Nicolas; Lu, Shun; Franke, Fabio; Li, Ziming; Danchaivijitr, Pongwut; Han, Ji-Youn; Sun, Jong-Mu; Sugawara, Shunichi, et al.

ArticleIssue Date2024CitationFUTURE ONCOLOGY, v.20, no.37, pp 2927 - 2936PublisherTAYLOR & FRANCIS LTD
1
STATISTICS
Total View:
Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

CONTACT US

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어